Navigation Links
Growing Prevalence of Asthma is Fueling Vigorous Industry Competition for Effective, Affordable Therapies
Date:9/17/2012

NEW YORK, Sept. 17, 2012 /PRNewswire/ -- Citeline®, an Informa business, reviewed clinical trial data presented at the European Respiratory Society (ERS) conference, held September 1-5, 2012 in Vienna, Austria, noting that classical fixed-dose combination (FDC) treatments remain a focus of industry sponsors, but that novel targeted asthma drugs may also be on the horizon for persistent asthma patients.

(Logo:  http://photos.prnewswire.com/prnh/20120917/NE75453LOGO )

Respiratory drug leader GSK presented largely positive results from five pivotal Relvar (formerly Relovair) asthma trials. The results, submitted in July as part of the company's regulatory filing for asthma in the EU, demonstrated improved efficacy and safety. Citeline's Trialtrove® database monitors the development of these novel, once-daily drugs for asthma, and notes that Novartis/Merck's QMF149 program is the closest competitor behind Relvar. However, since the QMF149 program is still in phase II trials and is shifting development to the Breezhaler device, a long road remains before regulatory submission, promising Relvar a spot as the only marketed once-daily inhaled corticosteroid/long-acting beta agonist (ICS/LABA) following its approval.

"In addition to these novel therapies, Trialtrove also monitors generic FDC development, and found the majority of ongoing phase III asthma trials are for generic FDCs administered using new delivery devices, such as Chiesi's NEXThaler, Orion Pharma's Easyhaler and Vectura's Gyrohaler.  The classical FDC treatment paradigm remains highly effective for many asthma patients, and more affordable generic versions of these drugs will present strong competition for blockbusters Advair and Symbicort," states Dr. Laura Runkel, Citeline's Associate Director of Autoimmune/Inflammation.

Trialtrove data tracks biologics in development for asthma, and many are now targeting subsets of patients uncontrolled by FDCs. The most numerous candidates in ongoing trials are IL-13 antagonists, including Novartis's QBX258, AstraZeneca's tralokinumab, Sanofi/Regeneron's dupilumab, and Roche's lebrikizumab. In results presented at ERS, Roche demonstrated that lebrikizumab treatment reduced serum periostin in periostin-high subjects. The drug is currently in two large phase III studies for persistent asthma.  "Compared with other asthma drugs in the pipeline, lebrikizumab has progressed rapidly through clinical trials," notes Dr. Runkel. "Further setting lebrikizumab apart from its competitors is the fact that Roche is the only sponsor currently employing a companion diagnostic in its asthma trials." The use of a validated companion diagnostic could provide the key advantage in selecting the subset of patients most likely to benefit from IL-13 antagonism. Although companion diagnostics are rarely used in asthma trials, Citeline's Pipeline® product confirms that their use overall is on the rise and is currently tracking 82 companion diagnostics intended for approval with specific drugs.

About Citeline

Citeline provides the world's most comprehensive real-time R&D intelligence to the pharmaceutical industry, covering global clinical trial, investigator and drug intelligence. Our data is drawn from over 20,000 unique sources and analyzed by the industry's largest team – over 250 full-time expert analysts and editors.  Our services combine both data and on-demand access to our analysts, to give you up-to-the-minute information and intelligence on which to base critical business decisions. For more information about Citeline visit www.Citeline.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Sean McIntosh
52 Vanderbilt Ave., 7th Floor
New York, NY 10017

Tel: +1.212.520.2741
Email: Sean.McIntosh@Citeline.com


'/>"/>
SOURCE Citeline
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Impact Advisors Named to Inc. 5000 List of Nations Fastest-Growing Companies
2. Kareo Recognized as the Fastest Growing Medical Office Software Company by Inc. Magazine
3. Diplomat Specialty Pharmacy Honored By Inc. Magazine as One Of The Nations Fastest-Growing Companies for Fourth Consecutive Year
4. Millennium Surgical Corp. Named to Inc. 5000 List of Fastest Growing Private Companies for The Second Year
5. Medical Alarm Concepts Begins Shipments To Europe - Company Ordering Additional Inventory To Keep Up With Growing Demand
6. Central Logic Named To 2012 Inc. 500 Fastest Growing Private Companies
7. Comprehensive Care Corporation Names Jairo Estrada Senior Management Advisor To Assist in Growing the Companys New Pharmacy Initiatives
8. Vesta Inc. Opens Frankfurt Office to Increase Service to Their Growing Medical Device Contracting Business Overseas
9. E-Prescribing Trend is Growing; Pennsylvania Ranks 11th in Nation
10. CPhI China 2012 Breaks Attendance Records in Growing Pharma Market
11. RD Legal Funding Provides Immediate Settlement Financing to Growing Number of Yaz and Yasmin Plaintiffs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Dec. 2, 2016 Lianluo Smart Limited ... "the Company") which develops, markets and sells medical ... China and international markets, recently ... and Treatment New Progress Forum, co-hosted by the ... Province , Guangdong Provincial People,s Hospital and ...
(Date:12/2/2016)... , Dec. 1, 2016 The concept of ... to be given to this sector has been taking shape ... since then the political aspects and initiatives related to orphan ... and at the level of member states individually. Many member ... 1990s in the space of orphan medicinal products, the result ...
(Date:12/2/2016)... Allergan plc (NYSE: AGN ), a ... previously announced Accelerated Share Repurchase (ASR) Program. Logo - ... ... previously announced, the Company entered into a variable tenor ASR ... repurchase $10 billion of its ordinary shares. Approximately 40.5 million ...
Breaking Medicine Technology:
(Date:12/2/2016)... CO (PRWEB) , ... December 02, 2016 , ... Advanced ... announced it has appointed Jason Bice, CPA, MBA to serve as Advanced Inc.’s Chief ... for Advanced, Inc. , Jason brings extensive financial and operational leadership experience to ...
(Date:12/2/2016)... ... 2016 , ... The annual time frame to change Medicare health and prescription ... December 7th. Currently-enrolled Medicare beneficiaries who are looking to switch from their current plan ... to make changes during this period order for their new policy to go into ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... two ostomy patients, standing as living proof that attitude and determination can combine ... and issues that spike around the holidays. This campaign will offer patients a ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet ... in USA Today, which covers the innovative treatments, therapeutic technologies, and revolutionized nutrition ... lives. “We are prolonging life 6 years in the last 3 decades,” says ...
(Date:12/2/2016)... OH (PRWEB) , ... December 02, 2016 , ... ... of veterinarian diagnostic imaging systems and the first company to offer ... With a Heart at their tradeshow booth # 941 for the American Association ...
Breaking Medicine News(10 mins):